Literature DB >> 7047549

Metabolic effects of prostaglandin E2 infusion in man: possible adrenergic mediation.

W P Newman, R G Brodows.   

Abstract

Infusion of prostaglandin E2 (PGE2) has been previously shown to inhibit acute insulin release and cause glucose intolerance. The present studies were undertaken to assess the effects of PGE2 on 1) pancreatic beta-cell sensitivity to glucose, 2) glucose tolerance, 3) tissue sensitivity to insulin, 4) glucose production and clearance, and 5) plasma catecholamine, glucagon, and FFA levels. Six healthy adult subjects were studied with the hyperglycemic clamp technique (plasma glucose 125 mg/dl above basal for 2 h) before and 30 min after the start of a PGE2 infusion (10 micrograms/min). Plasma epinephrine, norepinephrine, and FFA were measured during the PGE2 infusion. In additional experiments, glucose production and utilization were measured isotopically ([3-3H]glucose) during PGE2 infusion. PG infusion diminished, but not significantly, acute insulin release (0-10 min preinfusion, 172 +/- 36; postinfusion, 148 +/- 45 microunits/ml . 10 min). Late insulin release (20-120 min) was unchanged. A significant decline occurred in the amount of glucose metabolized from 9 +/- 1.1 to 7.2 +/- 1 mg/kg . min. During the initial 30 min of PGE2 infusion, plasma FFA increased by 26 +/- 6% (P less than 0.025). Plasma epinephrine and norepinephrine rose from 40 +/- 6 to 104 +/- 24 pg/ml (P less than 0.05) and 204 +/- 17 to 440 +/- 30 pg/ml (P less than 0.01), respectively. PGE2 produced a prompt 30% rise in glucose output, which declined to basal levels by 60 min. Glucose clearance decreased transiently at 45 min by 23%. We conclude that the effects on glucose homeostasis noted during PGE2 infusion occur in the face of heightened adrenergic activity. These metabolic responses closely resemble adrenergically induced changes in glucose homeostasis. As such, before any metabolic effects can be attributed directly to infused PGE2, any metabolic effects can be attributed directly to infused PGE2, the role of concomitant catecholamine release must be considered.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7047549     DOI: 10.1210/jcem-55-3-496

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.

Authors:  D Hartmann; A Korn; M Komjati; G Heinz; P Haefelfinger; R Defoin; W K Waldhäusl
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

2.  Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man.

Authors:  P R Bratusch-Marrain; H Vierhapper; M Komjati; W K Waldhäusl
Journal:  Diabetologia       Date:  1985-09       Impact factor: 10.122

3.  Protective effects of delayed intraventricular TLR7 agonist administration on cerebral white and gray matter following asphyxia in the preterm fetal sheep.

Authors:  Kenta H T Cho; Guido Wassink; Robert Galinsky; Bing Xu; Sam Mathai; Simerdeep K Dhillon; Lotte G van den Heuij; Joanne O Davidson; Luke Weaver-Mikaere; Laura Bennet; Alistair J Gunn; Mhoyra Fraser
Journal:  Sci Rep       Date:  2019-07-02       Impact factor: 4.379

4.  Perioperative Metabolites Are Associated With Adverse Neonatal Congenital Heart Disease Surgical Outcomes.

Authors:  Jessica Heibel; Eric M Graham; William T Mahle; Aurelie Roux; David Graham; Cedric Manlhiot; Allen D Everett
Journal:  J Am Heart Assoc       Date:  2022-08-10       Impact factor: 6.106

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.